Re-Aim Therapeutics
Latest round
- Seed
Last raised
- Oct 2025
Total raised
- $9.3M
Investors
- 2
About Re-Aim Therapeutics
Based in Oxford, UK, and founded in 2024 by Chief Scientific Officer Asher Maroof, Founder of Re-Aim Therapeutics; co-founder details are not publicly disclosed in the reviewed official sources, Re-Aim Therapeutics operates as a biotechnology company developing therapies for autoimmune diseases by targeting and reducing specific T cell populations associated with disease activity. Re-Aim Therapeutics focuses on developing targeted biologics for patients with T cell-driven autoimmune diseases. The company's offerings include monoclonal antibody candidates such as REA-001, designed to selectively deplete pathogenic T cells responsible for chronic inflammation. The firm provides a discovery platform that targets disease-relevant functional epitopes, enabling improved therapeutic selectivity.
Who invested in Re-Aim Therapeutics
2 investors across 1 round
See all investors in Re-Aim Therapeutics
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Seed
Oct 2, 2025
Amount
$9.3M
Investors
Questions about Re-Aim Therapeutics
Who invested in Re-Aim Therapeutics?
Re-Aim Therapeutics has 2 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Re-Aim Therapeutics raised?
Re-Aim Therapeutics has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Re-Aim Therapeutics last raise money?
Re-Aim Therapeutics's most recent round on record is a Seed, in Oct 2025.
What does Re-Aim Therapeutics do?
Based in Oxford, UK, and founded in 2024 by Chief Scientific Officer Asher Maroof, Founder of Re-Aim Therapeutics; co-founder details are not publicly disclosed in the reviewed official sources, Re-Aim Therapeutics operates as a biotechnology company developing therapies for autoimmune diseases by targeting and reducing specific T cell populations associated with disease activity.
Where is Re-Aim Therapeutics headquartered?
Re-Aim Therapeutics is headquartered in Oxford, UK.
Which VCs invest in companies like Re-Aim Therapeutics?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Balderton Capital back biotechnology companies at Re-Aim Therapeutics's stage. Their profiles are linked below.
VCs backing biotechnology startups at Seed
Raising like Re-Aim Therapeutics? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.